Blue Bird: An Unexpected Chance To Buy A Long-Term Compounder

Blue Bird Corporation is rated a buy after a 17% pullback, with DCF-based fair value at $77–81 per share, implying 18–24% upside. Q3 results were strong: $517M revenue beat, adjusted EPS met expectations, and FY26 EBITDA guidance was raised to $245–250M. Near-term risks include EPA Clean School Bus Program uncertainty and margin dilution from Micro Bird, but BLBD's diversified alt-power lineup cushions downside.